Literature DB >> 29520054

Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type.

Tommy Ivanics1, John R Bergquist2, Gang Liu1, Michael P Kim3, Yaan Kang3, Matthew H Katz3, Mayrim V Rios Perez3, Ryan M Thomas4,5, Jason B Fleming3, Mark J Truty6.   

Abstract

Patient-derived xenografts (PDX) are being increasingly utilized in preclinical oncologic research. Maintaining large colonies of early generation tumor-bearing mice is impractical and cost-prohibitive. Optimal methods for efficient long-term cryopreservation and subsequent reanimation of PDX tumors are critical to any viable PDX program. We sought to compare the performance of "Standard" and "Specialized" cryoprotectant media on various cryopreservation and reanimation outcomes in PDX tumors. Standard (10% DMSO media) and Specialized (Cryostor®) media were compared between overall and matched PDX tumors. Primary outcome was reanimation engraftment efficiency (REE). Secondary outcomes included time to tumor formation (TTF), time to harvest (TTH), and potential loss of unique PDX lines. Overall 57 unique PDX tumors underwent 484 reanimation engraftment attempts after previous cryopreservation. There were 10 unique PDX tumors cryopreserved with Standard (71 attempts), 40 with Specialized (272 attempts), and 7 with both (141 attempts). Median frozen time of reanimated tumors was 29 weeks (max. 177). Tumor pathology, original primary PDX growth rates, frozen storage times, and number of implantations per PDX model were similar between cryoprotectant groups. Specialized media resulted in superior REE (overall: 82 vs. 39%, p < 0.0001; matched: 97 vs. 36%, p < 0.0001; >52 weeks cryostorage: 59 vs. 9%, p < 0.0001), shorter TTF (overall 24 vs. 54 days, p = 0.0051; matched 18 vs. 53 days, p = 0.0013) and shorter TTH (overall: 64 vs. 89 days, p = 0.009; matched: 47 vs. 88 days, p = 0.0005) compared to Standard. Specialized media demonstrated improved REE with extended duration cryostorage (p = 0.048) compared to Standard. Potential loss of unique PDX lines was lower with Specialized media (9 vs. 35%, p = 0.017). In conclusion, cryopreservation with a specialized cryoprotectant appears superior to traditional laboratory-based media and can be performed with reliable reanimation even after extended cryostorage.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29520054      PMCID: PMC6072591          DOI: 10.1038/s41374-018-0042-7

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  45 in total

1.  Low-temperature storage of mammalian spermatozoa.

Authors:  C POLGE
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-12-17

2.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

Review 3.  Freezing of living cells: mechanisms and implications.

Authors:  P Mazur
Journal:  Am J Physiol       Date:  1984-09

4.  Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function.

Authors:  Meindert N Sosef; John M Baust; Keishi Sugimachi; Alex Fowler; Ronald G Tompkins; Mehmet Toner
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

5.  Low-molecular-weight carbohydrate Pentaisomaltose may replace dimethyl sulfoxide as a safer cryoprotectant for cryopreservation of peripheral blood stem cells.

Authors:  Jesper Dyrendom Svalgaard; Eva Kannik Haastrup; Kristian Reckzeh; Bjørn Holst; Peter Viktor Glovinski; Jette Sønderskov Gørløv; Morten Bagge Hansen; Kim Theilgaard Moench; Christian Clausen; Anne Fischer-Nielsen
Journal:  Transfusion       Date:  2016-03-15       Impact factor: 3.157

Review 6.  Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.

Authors:  Samuel A Williams; Wade C Anderson; Marianne T Santaguida; Scott J Dylla
Journal:  Lab Invest       Date:  2013-08-05       Impact factor: 5.662

7.  Intracellular ice formation during the freezing of hepatocytes cultured in a double collagen gel.

Authors:  A Hubel; M Toner; E G Cravalho; M L Yarmush; R G Tompkins
Journal:  Biotechnol Prog       Date:  1991 Nov-Dec

8.  On the mechanism of injury to slowly frozen erythrocytes.

Authors:  D E Pegg; M P Diaper
Journal:  Biophys J       Date:  1988-09       Impact factor: 4.033

Review 9.  Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.

Authors:  John W Cassidy; Carlos Caldas; Alejandra Bruna
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

10.  Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods.

Authors:  Nicolette G Alkema; Tushar Tomar; Evelien W Duiker; Gert Jan Meersma; Harry Klip; Ate G J van der Zee; G Bea A Wisman; Steven de Jong
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

View more
  7 in total

1.  Cryopreservation of Viable Human Tissues: Renewable Resource for Viable Tissue, Cell Lines, and Organoid Development.

Authors:  Andy He; Samantha Powell; Mason Kyle; Michael Rose; Edgar Masmila; Valeria Estrada; Jason K Sicklick; Alfredo Molinolo; Sharmeela Kaushal
Journal:  Biopreserv Biobank       Date:  2020-04-17       Impact factor: 2.300

Review 2.  Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.

Authors:  Magdalena Cybula; Magdalena Bieniasz
Journal:  Oncotarget       Date:  2022-03-24

3.  Cryopreservation of Whole Tumor Biopsies from Rectal Cancer Patients Enable Phenotypic and In Vitro Functional Evaluation of Tumor-Infiltrating T Cells.

Authors:  Frank Liang; Azar Rezapour; Peter Falk; Eva Angenete; Ulf Yrlid
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

4.  Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.

Authors:  Sarah Meneceur; Annett Linge; Matthias Meinhardt; Sandra Hering; Steffen Löck; Rebecca Bütof; Dietmar Krex; Gabriele Schackert; Achim Temme; Michael Baumann; Mechthild Krause; Cläre von Neubeck
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

5.  Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment.

Authors:  Matthew C Hernandez; Lin Yang; Jennifer L Leiting; Takaaki Sugihara; John R Bergquist; Tommy Ivanics; Rondell Graham; Mark J Truty
Journal:  Transl Oncol       Date:  2018-09-28       Impact factor: 4.243

6.  Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Authors:  Magdalena Cybula; Lin Wang; Luyao Wang; Ana Luiza Drumond-Bock; Katherine M Moxley; Doris M Benbrook; Camille Gunderson-Jackson; Maria J Ruiz-Echevarria; Resham Bhattacharya; Priyabrata Mukherjee; Magdalena Bieniasz
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

7.  3D-Printed Collagen Scaffolds Promote Maintenance of Cryopreserved Patients-Derived Melanoma Explants.

Authors:  Yun-Mi Jeong; ChulHwan Bang; MinJi Park; Sun Shin; Seokhwan Yun; Chul Min Kim; GaHee Jeong; Yeun-Jun Chung; Won-Soo Yun; Ji Hyun Lee; Songwan Jin
Journal:  Cells       Date:  2021-03-07       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.